Fused cyclic modulators of nuclear hormone receptor function
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07D-471/08
C07D-471/00
C07D-471/18
C07D-487/08
C07D-487/00
A61K-031/439
A61P-035/00
출원번호
US-0322306
(2002-12-18)
발명자
/ 주소
Salvati,Mark E.
Balog,James Aaron
Shan,Weifang
Giese,S철ren
Harikrishnan,Lalgudi S.
출원인 / 주소
Bristol Myers Squibb Company
인용정보
피인용 횟수 :
17인용 특허 :
84
초록▼
The invention pertains to fused cyclic compounds having the formula, wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7' or NR10 , and M' is a bond or NR10, with the proviso that at least one of M or M' must be a bond; E is C═Z2, CR7CR
The invention pertains to fused cyclic compounds having the formula, wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7' or NR10 , and M' is a bond or NR10, with the proviso that at least one of M or M' must be a bond; E is C═Z2, CR7CR 7', SO2, P═OR2, or P═OOR2; Z 1 is O, S, NH, or NR6; Z2 is O, S, NH, or NR 6; A1 is CR7 or N; A2 is CR7 or N; Y is J--J'--J" where J is (CR7R7')n and n=0-3, J' is a bond or O, S, S═O, SO2, NH, NR6, C═O, OC═O, NR1C═O, CR7R7', C═CR 8R8', R2P═O, OPOOR2, OPO2, OSO2, C═N, NHNH, NHNR6, NR6NH, N═N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J" is (CR7R7')n and n=0-3; W is CR7R7'--CR7R7', CR8═ CR8', CR7R7'--C═O, NR9--CR 7R7', N═CR8, N═N, NR9--NR 9', cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R2, R6, R7, R 7', R8, R8', R9, R9', and R 10 are as defined in the specification, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.
대표청구항▼
We claim: 1. A compound selected from the group consisting of: (5α ,8α,8aα)-8,8a-Dihydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-2,3,8,8a-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-3-thioxo-5,8-methanoimidazo[1,5-a]p
We claim: 1. A compound selected from the group consisting of: (5α ,8α,8aα)-8,8a-Dihydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-2,3,8,8a-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-3-thioxo-5,8-methanoimidazo[1,5-a]pyridin-1(5H)-one; (5α,8α,8aα)-8, 8a-Dihydro-8a-methyl-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2,3,8,8a-Tetrahydro-8a-methyl-3-thioxo-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazol[1,5-a]pyridin-1(5H)-one; (5α,8α,8aα)-2, 3,8,8a-Tetrahydro-2-(1-naphthalenyl)-3-thioxo-5,8-methanoimidazo[1,5-a] pyridin-1(5H)-one; (5α,8α,8aα)-Hexahydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1(5H)-one; (5α,8α,8aα)-2-[3,5-Bis(trifluoromethyl)phenyl]-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridin-1,3(2H,5H)-one; (5α, 8α,8aα)-8,8a-Dihydro-2-(2-naphthalenyl)-5,8-methanoimidazo[1, 5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-8,8a-Dihydro-2-(1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(3,5-Dichlorophenyl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α,8α, 8aβ)]-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1, 5-a]pyridine-1,3(2H,5H)-dione; [5R-(5α,8α,8αβ)]-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; Tetrahydro-2-(1-naphthalenyl)-5,8-ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; Tetrahydro-2-[3-(trifluoromethyl)phenyl]-5,8-ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(4-Bromo-1-naphthalenyl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α, 8α,8aβ)]-2-(3,5-Dichlorophenyl)tetrahydro-5,8-methanoimidazo[1, 5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aβ)]-2-(4-Bromo-1-naphthalenyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H, 5H)-dione; [5R-(5α,8α,8aβ)]-2-(4-Bromo-1-naphthalenyl) tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5R-(5α,8α,8aβ)]-2-(3,5-Dichlorophenyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-Hexahydro-2-(1-naphthaleny)-3-thioxo-5,8-methanoimidazo[1,5-a]pyridine-1(5H)-one; (5α,8α,8aβ)-Hexahydro-3-thioxo-2-[3-(trifluoromethyl) phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1(5H)-one; (5α,8α, 8aα)-2-(3,5-Dichlorophenyl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-Tetrahydro-2-[3-(trifluoromethyl) phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α, 8α,8aα)-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-Hexahydro-3-thioxo-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1(5H)-one; [5S-(5α,8α,8aα) ]-Tetrahydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-Tetrahydro-2-(2-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-Tetrahydro-2-(2-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-Tetrahydro-8a-methyl-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-8,8a-Dihydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-8,8a-Dihydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-Tetrahydro-8a-(2-propenyl)-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-Tetrahydro-8a-(phenylmethyl)-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [(Octahydro-1-oxo-2-phenyl-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene)amino]carbonitrile; (5α,8α,8aβ)-[[2-(3-Chloro-4-fluorophenyl)octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene] amino]carbonitrile; (5α,8α,8aα)-[[2-(3-Chloro-4-fluorophenyl)octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene] amino]carbonitrile; (5α,8α,8aβ)-2-(3-Chlorophenyl) tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α, 8α,8aα)-2-(3-Chlorophenyl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-[[2-(3-Chlorophenyl)octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene] amino]carbonitrile; (5α,8α,8aα)-[[2-(3-Chlorophenyl) octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene]amino] carbonitrile; (5α,8α,8αβ)-[[2-(3,5-Dichlorophenyl) octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene]amino] carbonitrile; (5α,8α,8aα)-[[2-(3,5-Dichlorophenyl) octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene]amino] carbonitrile; (5α,8α,8aα)-2-(3-Chloro-4-fluorophenyl) tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α, 8α,8aβ)-2-(3-Chloro-4-fluorophenyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-[[2-(3,4-Dichlorophenyl)octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene]amino]carbonitrile; (5α,8α,8aα)-[[2-(3,4-Dichlorophenyl)octahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3-ylidene]amino]carbonitrile; (5α,8α,8aβ)-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H, 5H)-dione; (5α,8α,8aα)-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-2-(3-Chloro-4-fluorophenyl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α, 8α,8aα)-2-(3-Chloro-4-fluorophenyl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-8,8a-Dihydro-8a-methyl-2-[4-nitro-3-(trifluoromethyl)phenyl]-5, 8-methanoimidazol[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl)benzonitrile; (5α,8α,8aα)-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl) benzonitrile; (5α,8α,8aα)-4-(1,2,3,5,8,8a-Hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl) benzonitrile; (5α,8α,8aα)-Hexahydro-2-(2-naphthaleny)-3-(phenylimino)-5,8-methanoimidazo[1,5-a]pyridine-1(5H)-one; (5α, 8α,8aβ)-2-Methoxy-4-(octahydro-1,3-dioxo-5,8-methanoimidazo[1, 5-a]pyridin-2-yl)-1-naphthalenecarbonitrile; (5α,8α,8aα)-2-Methoxy-4-(octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-1-naphthalenecarbonitrile; (5α,8α,8aα)-8a-[(4-Bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-5,8-methanoimidazo[1, 5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aβ)]-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1, 3(2H,5H)-dione; [5S-(5α,8α,8aα)]-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5R-(5α,8α,8aα)]-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5R-(5α,8α, 8aα)]-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl)benzonitrile; [5S-(5α,8α,8aβ)]-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aα)]-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1, 3(2H,5H)-dione; [5S-(5α,8α,8aβ)]-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl)benzonitrile; [5S-(5α,8α,8aα)]-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl)benzonitrile; (5α,8α,8aα)-2-(Benzo[b]thiophen-3-yl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5R-(5α,8α, 8aβ)]-4-(Octahydro-1,3-dioxo-5,8-methano-imidazo[1,5-a]pyridin-2-yl)-2-(trifluoromethyl)benzonitrile; [5R-(5α,8α,aα)]-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; [5R-(5α,8α,8aβ)]-Tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1, 3(2H,5H)-dione; [5R-(5α,8α,8aβ)]-Tetrahydro-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-8,8a-Dihydro-2-(1H-indol-3-yl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-2-(3-Chlorophenyl)-8,8a-dihydro-5,8-methano-imidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-8,8a-Dihydro-2-(1H-indol-3-yl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(Benzo[b]thiophene-3-yl)-8,8a-dihydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα) & (5α,8α,8aβ)-2-(1,2-Benzisoxazol-3-yl) tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α, 8α,8aα)-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a] pyridin-2-yl)-1-naphthalenecarbonitrile; (5α,8α,8aβ)-4-(Octahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-1-naphthalenecarbonitrile; (5α,8α,8aβ)-Tetrahydro-2-(1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-Tetrahydro-2-(1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-2-(4-Fluoro-1-naphthalenyl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-2-(4-Fluoro-1-naphthalenyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-2-(4-Chloro-1-naphthalenyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-2-(4-Chloro-1-naphthalenyl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-8,8a-Dihydro-2-(1-oxidobenzo[b]thiophen-3-yl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H, 5H)-dione; (5α,8α,8aα)-4-(1,2,3,5,8,8a-Hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2-yl)-1-naphthalenecarbonitrile; (5α,8α,8aα)-Tetrahydro-2-[4-(1H-tetrazol-5-yl)-1-naphthalenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(7-Fluoro-3-benzofuranyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-2-(7-Fluoro-3-benzofuranyl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aα)]-Tetrahydro-2-(2-methyl-4-nitrophenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aα)]-Tetrahydro-2-(3-methyl-4-nitrophenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; [5S-(5α,8α,8aα)]-Tetrahydro-7-methyl-2-(4-nitro-1-naphthalenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(2-Benzofuranyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-Tetrahydro-2-[3-methoxy-4-(4-oxazolyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aα)-Tetrahydro-2-(2-methyl-3-benzofuranyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aα)-2-(2,2-Dimethyl-2H-1-benzopyran-4-yl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-Tetrahydro-2-(2-methyl-4-nitrophenyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α,8aβ)-2-(2-Benzofuranyl)tetrahydro-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-Tetrahydro-2-(4,5,6,7-tetrafluoro-2-methyl-3-benzofuranyl)-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-Tetrahydro-2-[3-methoxy-4-(4-oxazolyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione; (5α,8α, 8aβ)-Tetrahydro-2-(2-methyl-3-benzofuranyl)-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; and (5α,8α,8aβ)-2-(2,2-Dimethyl-2H-1-benzopyran-4-yl)tetrahydro-5,8-methanoimidazo[1,5-a] pyridine-1,3(2H,5H)-dione; or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof. 2. A compound of the following formula (Ia) or (Ib): or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof; wherein the symbols have the following meanings and are, for each occurrence, independently selected: G is an aryl or heterocyclo group, where said group is mono-or polycyclic and is optionally substituted at one or more positions; A1 is CR7; A2 is CR7; Y is (CR7R7')n and n=1 or 2; Q is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, alkynyl or substituted alkynyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, halo, CN,--(C═O)OR1,--C(═O)R4,--C(═O)NR5R6,--C(R7R7')--OH, nitro,--(C2)OR1,--OR1,--C(═O)SR 1,--SO2R1,--NH2, or--NR4R 5; L is a bond, (CR7R7')n, NH, NR 5 or N(CR7R7')n, where n=0-2; R1 and R1' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, provided, however, that R1 and R1' are not hydrogen when attached to--SO2O--or--SO2--; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)OR1,--C(═O)NHR1,--SO2OR 1,--SO2R1 or--SO2NR1R 1'; R5 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)NHR1,--SO2OR1,--SO2R1 or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, CN,--OR1,--C(═O) R1,--C(═O)NHR1,--SO2R1,--SO2OR1 or--SO2NR1R1'; R7 and R7' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, hydroxylamine, hydroxylamide, NHR4,--NR2R5,--NHOR1, thiol, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O) R1,--C(═O)OR1,--PO3R1R 1',--C(═O)NR1R1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R 1,--SO2OR1 or--SO2NR1R 1'; or two groups R7 and R7' attached to the same carbon atom may be joined to form a spiro ring, or groups R7 and R7' attached to two adjacent carbon atoms may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring; R8 and R8' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, NHR4,--NR2 R5,--NHOR1, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--PO3R1R1',--C(═O)NR1R 1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R1,--SO2OR1 or--SO2NR1R1'; and or, groups R8 and R8' may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring; with the provisos that: (a) when A1 and A2 are both CH, Q is H, CH3, or--CO2CH3, and R7, R7' , R8 and R8' are at each occurrence hydrogen, then G--L considered together are not unsubstituted phenyl, 4-chlorophenyl, 4-methoxyphenyl, or benzyl; (b) when A1 and A2 are both CH, Q is H, and either or both of (i) R7 and R7' of the group Y, and (ii) R8 and R8', are taken together to form phenyl, then G--L is not 4-chlorophenyl or benzyl; and (c) when Q is H, Y is--CH2--CH2--, R7, R7', R8 and R8' are at each other occurrence hydrogen, then G--L--is not 4-chlorophenyl when (i) A1 and A2 are both C--CH3; and (ii) when A1 is C-isopropyl and A2 is C--CH3. 3. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, G is an aryl or heterocyclo group, where said group is mono-or polycyclic and is optionally substituted at one or more positions; Y is (CH2)n and n=1 or 2; Q is H, alkyl or substituted alkyl; L is a bond; R1 and R1' are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkylalkyl or substituted cycloalkylalkyl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O) OR1,--C(═O)NHR1,--SO2R1 or--SO2NR1R1'; R5 is alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl,--C(═O)R1,--SO2R1, or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, or CN; R7 and R7' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R5,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R1',--SO2R1, and--SO2NR1 R1'; and R8 and R8' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, CN, OR1, nitro, NHR4,--NR2R5, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1R1, SO 2R1, and--SO2NR1R1'. 4. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, having the formula (Ia), wherein, G is a di-substituted or tri-substituted phenyl or napthyl group; Q is H, alkyl or substituted alkyl; L is a bond; R1 and R1' are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkylalkyl or substituted cycloalkylalkyl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O) OR1,--C(═O)NHR1,--SO2R1 or--SO2NR1R1'; R5 is alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl,--C(═O)R1,--SO2R1, or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, or CN; R7 and R7' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R5,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R1',--SO2R1, and--SO2NR1 R1';and R8 and R8' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, CN, OR1, nitro, NHR4,--NR2R5, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1R1, SO 2R1, and--SO2NR1R1'. 5. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, having the formula (Ib), wherein, G is a di-substituted or tri-substituted phenyl or napthyl group; Q is H, alkyl or substituted alkyl; L is a bond; R1 and R1' are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkylalkyl or substituted cycloalkylalkyl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O) OR1,--C(═O)NHR1,--SO2R1 or--SO2NR1R1'; R5 is alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl,--C(═O)R1,--SO2R1, or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, or CN; R7 and R7' are at each occurrence independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R1,--C(═O)R5,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R1',--SO2R1, and--SO2NR1 R1'; R8 and R8' are at each occurrence independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, CN, OR1, nitro, NHR4,--NR2R5, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1R1, SO 2R1, and--SO2NR1R1'. 6. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, at least one of A1 and A2 is C(alkyl) or C(substituted alkyl); and Y is (CR7R7')n wherein n=1. 7. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, at least one of A1 and A2 is C(alkyl) or C(substituted alkyl); Y is (CR7R7')n wherein n=2; and at least one of R7, R7', R8 and R8' is other than hydrogen. 8. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, having the formula, wherein n is 1 or 2. 9. A compound according to claim 8, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, G is wherein R, R' and R" are selected from hydrogen, trifluoromethyl, methyl, halogen, cyano, nitro, OH, O(alkyl), alkyl, substituted alkyl, and cycloalkyl. 10. A compound according to claim 9, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, at least one of A1 and A2 is C(alkyl) or C(substituted alkyl); Q is H; and R7 and R7' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R5,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R1',--SO2R1, and--SO2NR1 R1'. 11. A compound according to claim 2, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, having the formula, wherein n is 1 or 2. 12. A compound according to claim 11, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, G is wherein R, R' and R" are selected from hydrogen, trifluoromethyl, methyl, halogen, cyano, nitro, OH, O(alkyl), alkyl, substituted alkyl, and cycloalkyl. 13. A compound according to claim 12, or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein, at least one of A1 and A2 is C(alkyl) or C(substituted alkyl); Q is H; and R8 and R8' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R5,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R1',--SO2R1, and--SO2NR1 R1'. 14. A compound having the formula (Ia*) or (Ib*), or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof; wherein the symbols have the following meanings and are, for each occurrence, independently selected: G is an aryl or heterocyclo group, where said group is mono-or polycyclic and is optionally substituted at one or more positions, provided that G is not 4-chlorophenyl; A1 is CR7; A2 is CR7; R1 and R1' are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, and aryl or substituted aryl; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkylalkyl or substituted cycloalkylalkyl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O) OR1,--C(═O)NHR1,--SO2R1 or--SO2NR1R1'; R5 is alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl,--C(═O)R1,--SO2R1, or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, or CN; R7 and R7' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, heterocycloalkyl or substituted heterocycloalkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, cyano, OR4,--NHR4,--NR2R5,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1 R140,--SO2R1, and--SO2NR1 R1', provided, however, that every group R7, R7' is not simultaneously hydrogen; R8 and R8' are independently at each occurrence selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, aryl or substituted aryl, halo, CN, OR1, nitro, NHR4,--NR2R5, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--C(═O)NR1R1, SO 2R1, and--SO2NR1R1'; and n=1 or 2. 15. A pharmaceutical composition comprising a compound according to claim 2, and a pharmaceutically-acceptable carrier. 16. A pharmaceutical composition of claim 15 further comprising another anti-cancer agent. 17. A method of modulating the function of the androgen receptor in a mammal which comprises administering to the mammal in need thereof an effective androgen receptor modulating amount of a compound of the following formula (Ia) or (Ib): or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof; wherein the symbols have the following meanings and are, for each occurrence, independently selected: G is an aryl or heterocyclo group, where said group is mono-or polycyclic and is optionally substituted at one or more positions; A1 is CR7; A2 is CR7; Y is (CR7R1')n and n=1 or 2; Q is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, alkynyl or substituted alkynyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, halo, CN,--(C═O)OR1,--C(═O)R4,--C(═O)NR5R6,--C(R7R7')--OH, nitro,--(CH2)OR1,--OR1,--C(═O)SR 1,--SO2R1,--NH2, or--NR4R 5; L is a bond, (CR7R7')n, NH, NR 5 or N(CR7R7')n, where n=0-2; R1 and R1' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, provided, however, that R1 and R1' are not hydrogen when attached to--SO2O--or--SO2--; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)OR1,--C(═O)NHR1,--SO2OR 1,--S2R1 or--SO2NR1R1' ; R5 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)NHR1,--SO2OR1,--SO2R1 or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, CN,--OR1,--C(═O) R1,--C(═O)NHR1,--SO2R1,--SO2OR1 or--SO2NR1R1', R7 and R7' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, hydroxylamine, hydroxylamide, NHR4,--NR2R5,--NHOR1, thiol, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O) R1,--C(═O)OR1,--PO3R1R 1',--C(═O)NR1R1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R 1,--SO2OR1 or--SO2NR1R 1'; or two groups R7 and R7' attached to the same carbon atom may be joined to form a spiro ring, or groups R7 and R7' attached to two adjacent carbon atoms may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring; R8 and R8' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, NHR4,--NR2 R5,--NHOR1, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--PO3R1R1',--C(═O)NR1R 1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R1,--SO2OR1 or--SO2NR1R1'; or, groups R8 and R8' may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring. 18. The method of claim 17 wherein said nuclear hormone receptor is the androgen receptor. 19. The method of claim 17 wherein said nuclear hormone receptor is selected from the estrogen receptor, the progesterone receptor, the glucocorticoid receptor, the mineralocorticoid receptor, the aldosterone receptor, the RORbeta receptor, and the COUP-TF2 receptor. 20. A method for treating a condition or disorder comprising administering to a mammalian species in need thereof a therapeutically effective amount of a compound of the following formula (Ia) or (Ib): or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof; wherein the symbols have the following meanings and are, for each occurrence, independently selected: G is an aryl or heterocyclo group, where said group is mono-or polycyclic and is optionally substituted at one or more positions; A1 is CR7; A2 is CR7; Y is (CR7R7')n and n=1 or 2; Q is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, alkynyl or substituted alkynyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, halo, CN,--(C═O)OR1,--C(═O)R4,--C(═O)NR5R6,--C(R7R7')--OH, nitro,--(CH2)OR1,--OR1,--C(═O)SR 1,--SO2R1,--NH2, or--NR4R 5; L is a bond, (CR7R7')n, NH, NR 5 or N(CR7R7')n, where n=0-2; R1 and R1' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, provided, however, that R1 and R1' are not hydrogen when attached to--SO2O--or--SO2--; R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl; R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)OR1,--C(═O)NHR1,--SO2OR 1,--SO2R1 or--SO2NR1R 1'; R5 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl,--C(═O)R1,--C(═O)NHR1,--SO2OR1,--SO2R1 or--SO2NR1R1'; R6 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, CN,--OR1,--C(═O) R1,--C(═O)NHR1,--SO2R1,--SO2OR1 or--SO2NR1R1'; R7 and R1' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, hydroxylamine, hydroxylamide, NHR4,--NR2R5,--NHOR1, thiol, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O) R1,--C(═O)OR1,--PO3R1R 1',--C(═O)NR1R1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R 1,--SO2OR1 or--SO2NR1R 1'; or two groups R7 and R7' attached to the same carbon atom may be joined to form a spiro ring, or groups R7 and R7' attached to two adjacent carbon atoms may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring; R8 and R8' are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, CN, OR1, nitro, NHR4,--NR2 R5,--NHOR4, alkylthio or substituted alkylthio,--C(═O)R1,--OC(═O)R1,--C(═O)OR1,--PO3R1R1',--C(═O)NR1R 1,--C(═O)SR1,--C(═O)NHSO2R1,--SOR1,--SO2R1,--SO2OR1 or--SO2NR1R1'; or, groups R8 and R8' may be joined to form a fused, optionally-substituted monocyclic or bicyclic heterocyclic or carbocyclic ring; wherein said condition or disorder is selected from the group consisting of benign prostate hypertrophia, hirsutism, ance, hyperpilosity, seborrhea, endometriosis, polycystic ovary syndrome, androgenic alopecia, hypogonadism, osteoporosis, suppressing spermatogenesis, libido, cachexia, anorexia, androgen supplementation for age related decreased testosterone levels in men, prostate cancer, breast cancer, endometrial cancer, and hot flashes. 21. The method of claim 20, wherein said compound has the formula, and said condition or disorder is prostate cancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (84)
Perronnet ; Jacques ; Girault ; Pierre ; Bonne ; Claude, 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl imidazolidines.
Moguilewsky Martine (Paris FRX) Bouton Marie M. (Paris FRX), Application of 1-(3′-trifluoromethyl-4′-nitrophenyl)-4,4′-dimethylimidazoline 2,5-dione in the treatment of hormone-d.
Vincent Michel (Bagneux FRX) Remond Georges (Versailles FRX) Laubie Michel (Vaucresson FRX), Azabicyclooctane-carboxylic acids and pharmaceutical compositions containing them and antihypertensive use thereof.
Schweikert Hans-Udo (Bonn-Roettgen DEX) Tunn Ulf (Castrup-Rauxel DEX) Senge Theodor (Castrup-Rauxel DEX) Nmann Friedmund (Berlin DEX), Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperpla.
Lubowitz Hyman R. (Rolling Hills Estates CA) Sheppard Clyde H. (Bellevue WA) Stephenson Ronald R. (Kirkland WA), Crosslinkable polyamideimide oligomers and a method of preparation.
Lubowtiz Hyman R. (Rolling Hills Estates CA) Sheppard Clyde H. (Post Falls ID), Heterocycle or heterocycle sulfone oligomers with multiple chemically functional end caps.
Miller Duane D. ; Kirkovsky Leonid I. ; Dalton James T. ; Mukherjee Arnab, Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer.
Sekut Les ; Carter Adam ; Ghayur Tariq ; Banerjee Subhashis ; Tracey Daniel E., Methods and compositions for modulating responsiveness to corticosteroids.
Sheppard Clyde H. (Boeing Aerospace Company ; P.O. Box 399 ; M/S 73-09 Seattle WA 98124-2499) Lubowitz Hyman R. (26 Coral Tree Ln. Rolling Hills Estates CA 90274), Methods for making liquid molding compounds using diamines and dicyanates.
Vincent Michel (Bagneux FRX) Remond Georges (Versailles FRX) Portevin Bernard (Elancourt FRX) Herve Yolande (Puteaux FRX) Lepagnol Jean (Chatou FRX) Biton Catherine (Nanterre FRX), New heterocyclic tripeptide compounds.
Claussner Andre,FRX ; Goubet Francois,FRX ; Teutsch Jean,FRX, Optionally substituted phenylimidazolidines, their preparation process and intermediates, their use as medicaments and.
Tesoro Giuliana C. (Dobbs Ferry NY) Sastri Vinod R. (Brooklyn NY) Narang Subash C. (Menlo Park CA), Siloxane-containing polyimide coatings for electronic devices.
Salvati, Mark E.; Attar, Ricardo M.; Gottardis, Marco M.; Balog, James Aaron; Pickering, Dacia A.; Martinez, Rogelio L.; Sun, Chongqing, Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function.
Henriksen,Dennis Bang; Holst,Jens Juul, Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.